Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Aug. 31, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Keryx Biopharmaceuticals (NASDAQ:KERX) over alleged Securities Laws Violations by Keryx Biopharmaceuticals. The lawsuit seeks to recover damages for certain NASDAQ:KERX investors.
Investors who purchased shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have certain options and for certain investors there are short and strict deadlines running. Deadline: October 3, 2016. NASDAQ:KERX investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product, that the issue was resulting in decreased production yields of finished drug product, that, as a result, the Company would, and did exhaust its reserve of finished drug product, and that, as a result of the foregoing, Defendants’ statements about Keryx Biopharmaceuticals’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On August, 1, 2016 Keryx Biopharmaceuticals announced an interruption in the supply of Auryxia® (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient to finished drug product. Keryx Biopharmaceuticals said it expects to make Auryxia available to patients when supply is back to adequate levels. Additionally, Keryx Biopharmaceuticals has withdrawn its 2016 financial guidance.
Those who purchased Keryx Biopharmaceuticals (NASDAQ:KERX) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
